ABAD: A Potential Therapeutic Target for Aβ-Induced Mitochondrial Dysfunction in Alzheimer's Disease

Amyloid-beta-peptide (Aβ) binding to mitochondrial Aβ-binding alcohol dehydrogenase (ABAD) enzyme triggers a series of events leading to mitochondrial dysfunction characteristic of Alzheimer's disease (AD). Thus this interaction may represent a novel target for treatment strategy against AD. In this review we summarize current findings regarding the ABAD-Aβ interaction, namely structural and biophysical data, available inhibitors and more recent data from proteomic studies.